SCHEMBL23620106

SCHEMBL23620106

O=[N+]([O-])c1cc(F)c(OCC(F)F)nc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.37
ATM Q13315 1/20 0.37
MAPT P10636 6/20 0.33
ALDH1A1 P00352 6/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
LMNA P02545 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
POLB P06746 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
PIN1 Q13526 1/20 0.33
KDM4E B2RXH2 1/20 0.33
THRB P10828 1/20 0.33
PKM P14618 1/20 0.33
IDO1 P14902 1/20 0.33
RECQL P46063 1/20 0.33
TDO2 P48775 1/20 0.33
BLM P54132 1/20 0.33
CASP6 P55212 1/20 0.33
MYC P01106 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30977413 0.86 CYP19A1 (0.33) TDP1ATMMAPTALDH1A1MEN1
SCHEMBL27036920 0.82 TDP1 (0.34) TDP1ATMMAPTALDH1A1MEN1
SCHEMBL30977471 0.81 TDP1 (0.38) TDP1ATMMAPTALDH1A1MEN1
SCHEMBL27175922 0.81 TDP1 (0.38) TDP1ATMMAPTALDH1A1MEN1
SCHEMBL29830193 0.76 ALDH1A1 (0.42) TDP1ATMMAPTALDH1A1PIN1
SCHEMBL13729984 0.76 ALDH1A1 (0.42) TDP1ATMMAPTALDH1A1PIN1
SCHEMBL31153432 0.76 PIN1 (0.55) ATMMEN1KMT2ALMNAPIN1
SCHEMBL21569528 0.74 TDP1 (0.40) TDP1ATMMAPTALDH1A1MEN1
SCHEMBL30271366 0.73 MERTK (0.51) TDP1MAPTPOLBL3MBTL1PIN1
SCHEMBL25009740 0.73 S1PR4 (0.36) TDP1ATMMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619402-A1 GPR17 MODULATORS AND USES THEREOF Myrobalan Therapeutics, Inc. (US) 2025-09-24 EP disclosed
CN-119613397-A N-heteroaromatic ring-3-sulfonamide compounds and use thereof for preparing GPR17 receptor inhibitors 迈巴制药(南京)有限公司 2025-03-14 CN disclosed
WO-2024104462-A1 GPR17 MODULATORS AND USES THEREOF MYROBALAN THERAPEUTICS NANJING CO. LTD (CN) 2024-05-23 WO disclosed
CN-112469710-B Pyridyl and pyrazinyl- (aza) indole sulfonamides 优时比制药有限公司 2024-05-14 CN disclosed
US-11939319-B2 Pyridinyl and pyrazinyl-(asa)indolsulfonamides UCB PHARMA GMBH (DE) 2024-03-26 US disclosed
US-11939319-B2 Pyridinyl and pyrazinyl-(asa)indolsulfonamides UCB PHARMA GMBH (DE) 2024-03-26 US disclosed
US-11939319-B2 Pyridinyl and pyrazinyl-(asa)indolsulfonamides UCB PHARMA GMBH (DE) 2024-03-26 US disclosed
EP-4074703-B1 PYRIDINYL-(AZA)INDOLSULFONAMIDES UCB PHARMA GMBH (DE) 2023-11-29 EP disclosed
EP-4074703-A1 PYRIDINYL-(AZA)INDOLSULFONAMIDES UCB Pharma GmbH (DE) 2022-10-19 EP disclosed
EP-3810591-B1 PYRIDINYL AND PYRAZINYL-(AZA)INDOLSULFONAMIDES UCB PHARMA GMBH (DE) 2022-08-10 EP disclosed
US-20210206749-A1 Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides UCB PHARMA GMBH (DE) 2021-07-08 US disclosed
CN-112469710-A Pyridyl and pyrazinyl- (aza) indole sulfonamides 优时比制药有限公司 2021-03-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210206749-A1 Pyridinyl and Pyrazinyl-(Asa)Indolsulfonamides GPR17, GPR18, GPR119 TDP1 3788/4885ATM 2493/4885MAPT 3406/4885
US-11939319-B2 Pyridinyl and pyrazinyl-(asa)indolsulfonamides GPR17, GPR18, GPR119 TDP1 3788/4885ATM 2493/4885MAPT 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.